Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
SNDX
Syndax Pharmaceuticals, Inc.
Company focuses on oncology therapeutics, including Revuforj and Niktimvo, placing Syndax in Biotech - Oncology.
|
$1.71B |
$19.88
+2.21%
|
|
STOK
Stoke Therapeutics, Inc.
TANGO uses antisense oligonucleotides to upregulate the healthy gene copy, directly categorizing the company’s core assets as an oligonucleotide therapeutic.
|
$1.71B |
$31.21
+4.66%
|
|
ZBIO
Zenas BioPharma, Inc.
Company focuses on immunology-based therapeutics for autoimmune diseases.
|
$1.71B |
$40.38
+1.30%
|
|
AGIO
Agios Pharmaceuticals, Inc.
Agios's strategic pivot to rare diseases centers on PK activation therapies and a pipeline addressing rare hematologic conditions, aligning with Biotech - Rare Diseases.
|
$1.69B |
$29.04
+2.16%
|
|
OMCL
Omnicell, Inc.
XT Series automated dispensing systems, XR2 robot, IVX compounding robot are medical devices and biometrics products.
|
$1.68B |
$36.65
-0.95%
|
|
MAZE
Maze Therapeutics, Inc.
Maze develops small molecule therapeutics, including MZE829 and MZE782, which are oral small molecule treatments for renal/cardiovascular/metabolic diseases.
|
$1.67B |
$37.98
+3.50%
|
|
AZTA
Azenta, Inc.
Azenta's automated sample storage and cryogenic systems fall under Medical Devices & Biometrics.
|
$1.66B |
$36.31
-4.70%
|
|
IMNM
Immunome, Inc.
Primary modality across the pipeline is Antibody-Drug Conjugates (ADCs).
|
$1.62B |
$18.61
+1.69%
|
|
TRVI
Trevi Therapeutics, Inc.
Trevi Therapeutics develops Haduvio, an oral small molecule therapeutic (nalbuphine ER) for chronic cough.
|
$1.62B |
$13.29
+16.95%
|
|
BHE
Benchmark Electronics, Inc.
Manufactures Medical Device Components for use in regulated medical devices.
|
$1.61B |
$44.93
+0.49%
|
|
TWFG
TWFG, Inc. Common Stock
Distributes health insurance products.
|
$1.61B |
$28.57
+1.08%
|
|
ACHC
Acadia Healthcare Company, Inc.
ACHC is a pure-play behavioral health provider delivering inpatient and outpatient mental health and substance use treatment services.
|
$1.58B |
$17.18
+3.71%
|
|
NEO
NeoGenomics, Inc.
They provide comprehensive laboratory testing services and advisory support for oncology diagnostics.
|
$1.57B |
$12.14
-1.62%
|
|
HROW
Harrow Health, Inc.
Direct ophthalmic drug products (VEVYE, IHEEZO, TRIESENCE, BYQLOVI) are core branded ophthalmic pharmaceuticals.
|
$1.53B |
$41.34
+0.78%
|
|
QURE
uniQure N.V.
Core business is development and commercialization of gene therapies (e.g., AMT-130) using viral vectors, i.e., direct gene therapy products.
|
$1.52B |
$27.60
-1.29%
|
|
UPB
Upstream Bio, Inc.
Verekitug is a monoclonal antibody therapeutic targeting the TSLP receptor, directly aligning with Monoclonal Antibody Therapeutics.
|
$1.51B |
$27.98
-2.93%
|
|
PHVS
Pharvaris N.V.
Pharvaris' lead program deucrictibant is an oral small-molecule therapeutic targeting Bradykinin B2 receptor for HAE/AAE, fitting the 'Oral Small Molecule Therapeutics' category.
|
$1.50B |
$27.80
+9.23%
|
|
BCRX
BioCryst Pharmaceuticals, Inc.
ORLADEYO is BioCryst's flagship oral small-molecule therapy for hereditary angioedema, a core product.
|
$1.49B |
$7.12
+3.94%
|
|
COLL
Collegium Pharmaceutical, Inc.
Jornay PM, Belbuca, Xtampza ER, and Nucynta are all oral small-molecule therapeutics, representing major product categories in Collegium's portfolio.
|
$1.46B |
$46.24
+1.40%
|
|
ARDX
Ardelyx, Inc.
Ardelyx's core offerings are oral, small-molecule therapeutics (IBSRELA and XPHOZAH) based on tenapanor.
|
$1.43B |
$5.95
+4.02%
|
|
NVCR
NovoCure Limited
NovoCure's TTFields cancer therapy device (Optune) is a medical device sold to treat cancer, fitting the Medical Devices & Biometrics category.
|
$1.43B |
$12.76
+0.95%
|
|
DNTH
Dianthus Therapeutics, Inc.
Lead product is a monoclonal antibody therapeutic targeting active C1s, a core product category.
|
$1.42B |
$44.02
-0.15%
|
|
TNDM
Tandem Diabetes Care, Inc.
Tandem Diabetes Care manufactures insulin pumps (medical devices) and biometric sensing data integration, a core medical device product line.
|
$1.40B |
$20.73
-5.06%
|
|
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
Core product is Cardiology devices: wearable defibrillator (ASSURE WCD) and related cardiac therapy platform.
|
$1.39B |
$27.00
-0.55%
|
|
RLAY
Relay Therapeutics, Inc.
Directly develops oncology therapies (lead asset RLY-2608) and precision medicine leveraging its platform.
|
$1.38B |
$8.03
-0.31%
|
|
INVA
Innoviva, Inc.
Zoliflodacin is an oral small-molecule therapeutic in Innoviva's pipeline, representing the IST focus on oral antibiotics.
|
$1.37B |
$21.70
-0.09%
|
|
URGN
UroGen Pharma Ltd.
ZUSDURI (UGN-102) is an oncology therapeutic developed by UroGen, placing the company in Biotech - Oncology.
|
$1.36B |
$29.43
+6.28%
|
|
CNMD
CONMED Corporation
A large share of revenues comes from single-use disposable medical device products, i.e., consumables.
|
$1.35B |
$43.74
+1.11%
|
|
BBNX
Beta Bionics, Inc.
Core product is a medical device (iLet Bionic Pancreas) and related biometrics in diabetes care.
|
$1.34B |
$30.95
-1.78%
|
|
DVAX
Dynavax Technologies Corporation
HEPLISAV-B is a hepatitis B vaccine, representing the company's flagship vaccine product.
|
$1.34B |
$11.44
-0.26%
|
|
AMLX
Amylyx Pharmaceuticals, Inc.
AMX0035 is an oral fixed-dose combination therapy, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$1.34B |
$15.01
+0.84%
|
|
TSHA
Taysha Gene Therapies, Inc.
TSHA-102 is an AAV9-based gene therapy product directly developed by Taysha for Rett syndrome.
|
$1.33B |
$4.87
+6.10%
|
|
SEPN
Septerna, Inc.
Septerna is focused on discovering and developing oral small molecule therapeutics targeting GPCRs (e.g., preclinical metabolic programs and GPCR targets under Novo Nordisk collaboration), which maps to the 'Oral Small Molecule Therapeutics' investable theme.
|
$1.32B |
$29.71
+6.22%
|
|
TDOC
Teladoc Health, Inc.
Integrated Care delivers virtual medical, mental health, and chronic condition management services.
|
$1.32B |
$7.46
|
|
NRIX
Nurix Therapeutics, Inc.
Lead candidate NX-5948 is an orally bioavailable degrader, confirming the company’s core business in Oral Small Molecule Therapeutics.
|
$1.31B |
$17.19
+1.12%
|
Showing page 12 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
